Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 10, 2012, Pages 5409-5413

  Lepist, Eve Irene ^a   Phan, Truc K ^a   Roy, Anupma ^a   Tong, Leah ^a   MacLennan, Kelly ^a   Murray, Bernard ^a   Ray, Adrian S ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; COBICISTAT; DARUNAVIR; DIGOXIN; GLYCOPROTEIN P; GS 7340; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; PRAZOSIN; RITONAVIR; TENOFOVIR DISOPROXIL; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG EFFECT; DRUG PENETRATION; DRUG POTENCY; DRUG SOLUBILITY; DRUG TRANSPORT; IN VITRO STUDY; INTESTINE ABSORPTION; PRIORITY JOURNAL;

ADENINE; CACO-2 CELLS; CARBAMATES; HIV PROTEASE INHIBITORS; HUMANS; INTESTINAL ABSORPTION; THIAZOLES;

EID: 84866329673     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01089-12     Document Type: Article

References (21)

1. Callebaut C, et al. 2011. In vitro characterization of GS-8374, a novel phosphonate-containing inhibitor of HIV-1 protease with a favorable resistance profile. Antimicrob. Agents Chemother. 55:1366-1376.
2. Cohen C, et al. 2011. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 25:7-12.
3. DeJesus E, et al. 2012. Week 48 results of an ongoing global phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) with atazanavir/ritonavir plus emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects showing efficacy, safety, and pharmacokinetics, abstr 627. Abstr. 19th Conf. Retrovir. Opportunistic Infect. CROI, Alexandria, VA. http://www.retroconference.org/2012b/Abstracts/43391.htm.
4. Ding R, et al. 2004. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76:73-84. (Pubitemid 38844736)
5. European Medicines Agency. 2010. European Medicines Agency guidelines on the investigation of drug interactions. European Medicines Agency, London, England. http://www.ema.europa.eu/ema/doc-index.jsp?curl=pages/includes/ document/document-detail.jsp?webContentId=WC500090112&murl=menus/ document-library/document-library.jsp&mid=0b01ac058009a3dc.
6. Food and Drug Administration. 2012. Food and Drug Administration guidance for industry: drug interaction studies. Study design, data analysis, implications for dosing and labeling recommendations. US FDA, Rockville, MD. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM292362.pdf.
7. German P, Warren D, West S, Hui J, Kearney BP. 2010. Pharmacokinetics and bioavailability of an integrase and novel pharmacoenhancercontaining single-tablet fixed-dose combination regimen for the treatment of HIV. J. Acquir. Immune Defic. Syndr. 55:323-329.
8. German P, et al. 2011. The effect of cobicistat and cytochrome P450 2D6, 2B6 and P-glycoprotein using phenotypic probes. Abstr. 12th Int. Workshop Clin. Pharmacol. HIV Ther. Virology Education B.V., Utrecht, The Netherlands.
9. Giacomini KM, et al. 2010. Membrane transporters in drug development. Nat. Rev. Drug Discov. 9:215-236.
10. Hidalgo IJ, Raub TJ, Borchardt RT. 1989. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 96:736-749. (Pubitemid 19057595)
11. Kim RB, et al. 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101:289-294. (Pubitemid 28067324)
12. Lee WA, et al. 2005. Selective intracellular activation of a novel prodrug of the human immunodeficiency virus reverse transcriptase inhibitor tenofovir leads to preferential distribution and accumulation in lymphatic tissue. Antimicrob. Agents Chemother. 49:1898-1906. (Pubitemid 40631605)
13. Mathias AA, et al. 2010. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin. Pharmacol. Ther. 87:322-329.
14. Penzak SR, et al. 2004. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther. Drug Monit. 26:322-330. (Pubitemid 38703022)
15. Polli JW, et al. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm. Res. 16:1206-1212. (Pubitemid 29393608)
16. Ramanathan S, Mathias AA, German P, Kearney BP. 2011. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin. Pharmacokinet. 50:229-244.
17. Ramanathan S, et al. 2012. Pharmacokinetics of a novel EVG/COBI/FTC/GS-7340 single tablet regimen, abstr O-13. Abstr. 13th Int. Workshop Clin. Pharmacol. HIV Ther. Virology Education B.V., Utrecht, The Netherlands.
18. Ray AS, et al. 2006. Mechanism of active renal tubular efflux of tenofovir. Antimicrob. Agents Chemother. 50:3297-3304. (Pubitemid 44527501)
19. Sax P, et al. 2012. Elvitegravir/cobicistat/emtricitabine/tenofovir (Quad) has non-inferior efficacy and favorable safety compared to efavirenz/emtricitabine/tenofovir in treatment-naïve HIV-1+ subjects, abstr 101. Abstr. 19th Conf. Retrovir. Opportunistic Infect. CROI, Alexandria, VA. http://www.retroconference.org/2012b/Abstracts/43143.htm.
20. Tong L, et al. 2007. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51:3498-3504. (Pubitemid 47519335)
21. Xu L, et al. 2010. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med. Chem. Lett. 1:209-213.